Anti-la SSB-IgG Antibodies by EIA

Blood

Report in 120Hrs

At Home

No Fasting Required

Details

Detects anti-La antibodies.

₹2,368₹3,383

30% OFF

Anti-La SSB-IgG Antibodies by EIA - Comprehensive Medical Test Information Guide

1. Why is it done?
- Test Description: This test detects Anti-La/SSB-IgG antibodies, which are autoimmune antibodies directed against the La/SSB (Sjögren's syndrome B) antigen, a protein found in the nucleus and cytoplasm of cells. The test uses Enzyme Immunoassay (EIA) technology to identify and measure these specific immunoglobulin G (IgG) antibodies in the blood.
- Primary Indications for Testing: • Diagnosis of Primary Sjögren's Syndrome (pSS) - a chronic autoimmune disorder affecting salivary and lacrimal glands • Investigation of secondary Sjögren's syndrome in patients with other autoimmune conditions (rheumatoid arthritis, lupus) • Evaluation of unexplained dry eyes (xerophthalmia) or dry mouth (xerostomia) • Assessment of patients with recurrent parotitis or persistent gland swelling • Evaluation of systemic lupus erythematosus (SLE) or connective tissue disease • Investigation of neuropathy or other systemic symptoms suggestive of autoimmune disease
- Typical Timing and Clinical Circumstances: • Initial diagnostic workup when Sjögren's syndrome is suspected • Part of comprehensive autoimmune panel evaluation • During assessment of patients with undifferentiated connective tissue disease • In monitoring of established autoimmune conditions • When other autoimmune markers are present or when clinical suspicion is high
2. Normal Range
- Reference Range Values: • Negative/Normal: < 1.0 EIA Units (EU) or < 1.0 International Units (IU/mL) • Borderline/Equivocal: 1.0 - 1.5 EIA Units • Positive: > 1.5 EIA Units • Note: Reference ranges may vary slightly between laboratories and EIA platforms used
- Units of Measurement: Results are typically reported in EIA Units (EU), International Units (IU/mL), or as a qualitative result (Negative/Positive). Some laboratories may report optical density (OD) values or index values.
- Interpretation of Results: • Negative Result: Absence of Anti-La/SSB-IgG antibodies; indicates autoimmune Sjögren's syndrome is unlikely, though does not completely exclude seronegative Sjögren's syndrome • Borderline Result: Requires clinical correlation and may warrant repeat testing or additional antibody testing (Anti-Ro/SSA antibodies) • Positive Result: Presence of Anti-La/SSB-IgG antibodies; strongly associated with autoimmune Sjögren's syndrome diagnosis, particularly when accompanied by clinical symptoms and other positive autoimmune markers
- Clinical Significance: Normal results suggest the patient does not have antibody-mediated autoimmune Sjögren's syndrome. Abnormal results indicate the presence of circulating Anti-La/SSB-IgG antibodies, which are highly specific for Sjögren's syndrome and almost always found in conjunction with Anti-Ro/SSA antibodies.
3. Interpretation
- Detailed Result Interpretation: • Low/Negative Values (< 1.0 EU): Suggests absence of Anti-La/SSB-IgG antibodies; patient likely does not have antibody-associated Sjögren's syndrome. However, seronegative Sjögren's syndrome remains possible if clinical suspicion is high. • Mildly Elevated/Borderline Values (1.0-1.5 EU): Warrants further investigation; consider clinical context and repeat testing. May represent early disease, false positive, or borderline positivity. • Moderately to Highly Elevated Values (> 1.5 EU): Strongly positive; highly suggestive of Sjögren's syndrome, particularly in symptomatic patients. Higher titers often correlate with more active disease.
- Clinical Significance of Results: • Positive Anti-La/SSB-IgG indicates Primary Sjögren's Syndrome: These antibodies are found in approximately 40-50% of pSS patients and are highly specific (>95% specificity) • Almost Always Accompanied by Anti-Ro/SSA: Approximately 95% of Anti-La/SSB-positive patients are also Anti-Ro/SSA positive • Secondary Sjögren's Association: May be found in 5-10% of SLE patients and other connective tissue diseases • Increased Risk of Systemic Manifestations: Presence of Anti-La/SSB associated with higher risk of peripheral neuropathy, lymphoma, and renal involvement
- Factors Affecting Test Results: • Disease Activity: Higher titers may correlate with more active disease • Disease Duration: Antibodies may develop over time in progressive autoimmune disease • Concurrent Medications: Immunosuppressive therapy may affect antibody titers • Individual Immune Response: Natural variation in antibody production • Laboratory Platform: Different EIA platforms may yield slightly different results • Cross-Reactivity: Occasional false positives in patients with other autoimmune conditions • Recent Vaccination or Infection: May transiently affect antibody levels
- Diagnostic Criteria Integration: Anti-La/SSB-IgG positivity is one of the objective criteria in the 2016 American College of Rheumatology classification criteria for Sjögren's syndrome. A positive result, combined with appropriate clinical features (ocular/oral symptoms), other autoimmune markers (Anti-Ro/SSA, rheumatoid factor), and potential imaging/biopsy findings, supports the diagnosis of Sjögren's syndrome.
4. Associated Organs
- Primary Organ Systems Involved: • Exocrine Glands: Salivary glands (parotid and submandibular), lacrimal glands • Immune System: B cells, T cells, dendritic cells involved in autoimmune response • Epithelial Tissues: Target tissues expressing La/SSB antigens • Systemic Manifestations: Can involve kidney, liver, lungs, nervous system, blood vessels
- Diseases Commonly Associated with Abnormal Results: • Primary Sjögren's Syndrome (pSS): Autoimmune disorder affecting salivary and lacrimal glands (40-50% positive) • Secondary Sjögren's Syndrome: Associated with rheumatoid arthritis, systemic lupus erythematosus, primary biliary cholangitis, primary sclerosing cholangitis • Systemic Lupus Erythematosus (SLE): Approximately 5-10% of SLE patients are Anti-La/SSB positive • Other Connective Tissue Diseases: May be found in overlap syndromes • Neonatal Lupus and Congenital Heart Block: In pregnant Anti-La/SSB-positive women • Lymphoproliferative Disorders: Increased risk of lymphoma in Anti-La/SSB-positive patients
- Systemic Manifestations and Complications: • Glandular Involvement: Chronic dry mouth (xerostomia), dry eyes (xerophthalmia), recurrent parotitis, tooth decay • Neurological: Peripheral neuropathy, central nervous system involvement, cognitive dysfunction • Renal: Tubulointerstitial nephritis, glomerulonephritis, renal tubular acidosis • Pulmonary: Interstitial lung disease, pulmonary fibrosis, lymphocytic infiltration • Hepatic: Autoimmune hepatitis, primary biliary cholangitis • Hematologic: Lymphopenia, anemia, thrombocytopenia, cryoglobulinemia • Lymphoproliferative: Increased risk (5-10% over 10 years) of non-Hodgkin's lymphoma • Systemic: Fatigue, fever, arthralgia, myalgia, vasculitis
- Potential Risks Associated with Abnormal Results: • Progressive Glandular Dysfunction: Worsening xerostomia and xerophthalmia • Development of Systemic Complications: Neuropathy, renal disease, pulmonary involvement • Malignancy Risk: Elevated lymphoma risk requiring monitoring • Secondary Infections: Due to disrupted mucosal barriers • Quality of Life Impact: Chronic symptoms affecting eating, speaking, vision • Pregnancy Complications: In women, risk of neonatal lupus and congenital heart block
5. Follow-up Tests
- Recommended Additional Tests Based on Results: • If Positive Anti-La/SSB-IgG: - Anti-Ro/SSA-IgG Antibodies: Essential; nearly all Anti-La/SSB patients are also Anti-Ro/SSA positive - Rheumatoid Factor (RF): Assess for other autoimmune markers - Antinuclear Antibodies (ANA): Screen for related autoimmune conditions - Complete Blood Count (CBC): Evaluate for cytopenias - Comprehensive Metabolic Panel (CMP): Assess kidney and liver function - Salivary Gland Flow Testing: Confirm functional impairment - Schirmer Test: Evaluate lacrimal gland function - Salivary Gland Biopsy: If diagnosis remains unclear - Imaging (Ultrasound or MRI): Evaluate gland structure and inflammation
- Further Investigations and Monitoring: • Initial Comprehensive Evaluation: - Liver function tests (LFTs): Assess for autoimmune hepatitis or cholangitis - Renal function tests: Baseline creatinine, urinalysis, assess for glomerulonephritis - Pulmonary function tests and chest imaging: If respiratory symptoms present - Peripheral blood smear: Evaluate for cryoglobulinemia or lymphoma - Thyroid function tests: Screen for associated thyroiditis • Baseline Surveillance: - Audiometry: Hearing loss can occur - Ophthalmology consultation: Comprehensive eye examination - Dental assessment: Risk of accelerated caries
- Ongoing Monitoring Frequency: • Routine Follow-up: Every 6-12 months for stable patients • With Active Symptoms: Every 3-6 months • On Immunosuppressive Therapy: Every 3-6 months to monitor treatment response • Annual Screening: CBC, CMP to monitor for cytopenias or organ involvement • Cancer Surveillance: Annual clinical examination; low-dose CT chest and abdominal imaging every 2-3 years to screen for lymphoma • Antibody Titer Monitoring: Repeat Anti-La/SSB and Anti-Ro/SSA testing may be performed to assess disease activity, though clinical correlation is essential
- Complementary and Related Tests: • Anti-Ro/SSA-IgG: Nearly always positive with Anti-La/SSB; most frequently checked companion test • Anti-muscarinic-3 (M3) Receptor Antibodies: Measure functional antibodies affecting gland secretion • Cryoglobulins (Qualitative and Quantitative): Associated with systemic complications • Immunoglobulin Levels (IgG, IgA, IgM): Assess hypergammaglobulinemia • Free Light Chains: Screen for monoclonal gammopathy or lymphoma • Tissue Biopsy (Salivary Gland): Histopathology confirmation of Sjögren's syndrome • Imaging Studies: Salivary gland ultrasonography, MR sialography, parotid scintigraphy
6. Fasting Required?
- Fasting Requirement: NO - Fasting is not required for Anti-La SSB-IgG antibody testing by EIA. This is a serology test that measures circulating antibodies and is not affected by food intake or fasting status.
- Patient Preparation Instructions: • Food and Beverage: Patient may eat and drink normally before the test • Timing: Can be performed at any time of day • No Special Preparation: No unusual dietary restrictions apply • Routine Activities: Patient may engage in normal daily activities
- Medications and Supplements: • No Medications to Avoid: There are no medications that need to be discontinued before this antibody test • Continue All Regular Medications: Immunosuppressive agents, antirheumatic drugs, corticosteroids, and other regular medications should be continued as prescribed • Important Note: Current immunosuppressive therapy may reduce antibody titers but does not contraindicate testing • Inform Phlebotomist: Notify the healthcare provider or phlebotomist of all current medications for clinical context
- Additional Preparation Requirements: • Specimen Collection: Simple venipuncture; typically 1-3 mL of serum required • Arm Preparation: Clean arm accessible for blood draw • Hydration: Adequate hydration may help with blood draw but is not specifically required • Rest: Brief rest before blood draw may help relax patient if anxious • Recent Illness: Test may be performed even if patient recently had infection or fever; timing should be discussed with ordering physician • Pregnancy: Testing is safe during pregnancy; no special precautions needed for the test itself, though clinical management implications exist

How our test process works!